A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone

World Journal of Biological Psychiatry

Volumn 9, Issue 3, 2008, Pages 219-224

  Vieta, Eduard ^a   Nieto, Evaristo ^b   Autet, Aurea ^c   Rosa, Adriane R ^a,c   Goikolea, Jose M ^a   Cruz, Nuria ^a   Bonet, Pere ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Althaia   (Spain)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Adherence; Antipsychotic; Bipolar disorder; Long acting risperidone; Mania

Indexed keywords

AMISULPRIDE; ANTIPARKINSON AGENT; CARBAMAZEPINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LONG ACTING DRUG; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID; ZIPRASIDONE;

ADULT; AGGRESSION; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; IMPOTENCE; MAINTENANCE THERAPY; MALE; MENTAL PATIENT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RELAPSE; SIDE EFFECT; SUICIDE ATTEMPT; TREATMENT DURATION; WEIGHT GAIN;

ADULT; BIPOLAR DISORDER; DELAYED-ACTION PREPARATIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISPERIDONE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 47749109614     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970701530917     Document Type: Article

References (30)

1. Barnes, TR and Curson, DA. (1994) Long-term depot antipsychotics. A risk-benefit assessment. 10, pp. 464-479.
2. Bhanji, NH, Chouinard, G. and Margolese, HC. (2004) A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. 14, pp. 87-92.
3. Colom, F., Vieta, E. Reinares, M. et al. (2003) Psychoeducation efficacy in bipolar disorders: Beyond compliance enhancement. 64, pp. 1101-1105.
4. Esparon, J., Kolloori, J., Naylor, GJ, McHarg, AM, Smith, AH and Hopwood, SE. (1986) Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. 148, pp. 723-725.
5. Fleischhacker, WW, Lemmens, P. and van Baelen, B. (2001) A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database. 34, pp. 104-110.
6. Ghaemi, SN, Hsu, DJ, Rosenquist, KJ, Katzow, JJ and Goodwin, FK. (2004) Long-term observational comparison of risperidone and olanzapine in bipolar disorder. 16, pp. 69-73.
7. Gurovich, I., Kobina, S. and Lyubov, E. (2001) A pharmacoeconomic analyses of depot neuroleptic treatment in natural setting. 3, p. 79.
8. (1976) National Institute of Mental Health, Rockville, MD
9. Harvey, PD, Green, MF, McGurk, SR and Meltzer, HY. (2003) Changes in cognitive functioning with risperidone and olanzapine treatment: A large-scale, double-blind, randomized study. 169, pp. 404-411.
10. Hirschfeld, RM, Eerdekens, M. Kalali, AH et al. (2006) An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder. 21, pp. 11-20.
11. Kane, JM, Eerdekens, M., Lindenmayer, JP, Keith, SJ, Lesem, M. and Karcher, K. (2003) Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. 160, pp. 1125-1132.
12. Keck Jr, PE, McElroy, SL Strakowski, SM et al. (1998) 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. 155, pp. 646-652.
13. Keefe, RS, Young, CA, Rock, SL, Purdon, SE, Gold, JM and Breier, A. (2006) One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. 81, pp. 1-15.
14. Khanna, S., Vieta, E., Lyons, B., Grossman, F., Eerdekens, M. and Kramer, M. (2005) Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study. 187, pp. 229-234.
15. Leal, A., Rosillon, D., Mehnert, A., Jarema, M. and Remington, G. (2004) Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. 13, pp. 811-816.
16. Lindenmayer, JP, Jarboe, K., Bossie, CA, Zhu, Y., Mehnert, A. and Lasser, R. (2005) Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. 20, pp. 213-221.
17. Lowe, MR and Batchelor, DH. (1986) Depot neuroleptics and manic depressive psychosis. 1, pp. 53-62.
18. Marken, PA, Stanislav, SW, Lacombe, S., Pierce, C., Hornstra, R. and Sommi, RW. (1992) Profile of a sample of subjects admitted to an acute care psychiatric facility with manic symptoms. 28, pp. 201-205.
19. Nayak, RK, Doose, DR and Nair, NP. (1987) The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. 27, pp. 144-150.
20. Reinares, M., Martinez-Aran, A., Colom, F., Benabarre, A., Salamero, M. and Vieta, E. (2000) Long-term effects of the treatment with risperidone versus conventional neuroleptics on the neuropsychological performance of euthymic bipolar patients]. 28, pp. 231-238.
21. Schumann, C., Lenz, G., Berghofer, A. and Muller-Oerlinghausen, B. (1999) Non-adherence with long-term prophylaxis: A 6-year naturalistic follow-up study of affectively ill patients. 89, pp. 247-257.
22. Scott, J. and Pope, M. (2002) Nonadherence with mood stabilizers: prevalence and predictors. 63, pp. 384-390.
23. Svarstad, BL, Shireman, TI and Sweeney, JK. (2001) Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. 52, pp. 805-811.
24. Vieta, E. and Rosa, AR. (2007) Evolving trends in the long-term treatment of bipolar disorder. 8, pp. 4-11.
25. Vieta, E., Herraiz, M. Fernandez, A. et al. (2001) Efficacy and safety of risperidone in the treatment of schizoaffective disorder: Initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD). 62, pp. 623-630.
26. Vieta, E., Herraiz, M., Parramon, G., Goikolea, JM, Fernandez, A. and Benabarre, A. (2002) Risperidone in the treatment of mania: Efficacy and safety results from a large, multicentre, open study in Spain. 72, pp. 15-19.
27. Vieta, E., Goikolea, JM Olivares, JM et al. (2003) 1-year follow-up of patients treated with risperidone and topiramate for a manic episode. 64, pp. 834-839.
28. Vieta, E., Brugue, E. Goikolea, JM et al. (2004) Acute and continuation risperidone monotherapy in mania. 19, pp. 41-45.
29. Weiden, PJ and Olfson, M. (1995) Cost of relapse in schizophrenia. 21, pp. 419-429.
30. White E, Cheung P, Silverstone P. 1993. Depot antipsychotics in bipolar affective disorder. 8 pp 119-122.